Germany-based biomedical technology company Biotronik has obtained CE Mark approval for its PK Papyrus covered coronary stent system for use in the treatment of acute coronary artery perforation.
According to Biotronik, the company's PK Papyrus device boasts 58% greater flexibility when compared to Abbott's Jostent Graftmaster due to its 'electrospun' 90μm polyurethane membrane.
PK Papyrus incorporates electrospinning technology that allows for a proprietary single-layer covered stent design, enabling a 24% lower crossing profile when compared to Abbott's Jostent Graftmaster.
The device offers high flexibility and a low crossing profile for exceptional deliverability, while also sealing vessel defects in acute situations.
The 5 F- and 6 F- compatible PK Papyrus eliminates the need to switch access catheters during emergency situations.
Biotronik Vascular Intervention vice president marketing Dr Alexander Uhl noted PK Papyrus is a testament to the engineering excellence at the company.
"The application of this electrospinning technology to the already highly deliverable BIOTRONIK Orsiro/PRO-Kinetic Energy stent platform has allowed us to introduce a novel product to the market that will enable physicians to treat patients in emergency situations quickly and safely," Dr Uhl added.
PK Papyrus is based on Orsiro/PRO-Kinetic Energy stent platform and has diameters ranging between 2.5-5.0mm and length between 15-26mm.
This wide size range of the device enables it to treat a broad range of vessels confidently and efficiently.
